(Q33426563)

26 July 2017

Therapeutic strategies for inhibiting invasion in glioblastoma (English)

1 reference

26 July 2017

1 reference

3

Patrick Y Wen

1 reference

26 July 2017

Jan Drappatz

1

1 reference

PubMed ID

19344303

26 July 2017

Andrew D Norden

series ordinal

2

1 reference

26 July 2017

1 April 2009

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

26 July 2017

1 reference

26 July 2017

9

1 reference

26 July 2017

519-534

1 reference

26 July 2017

4

1 reference

Malignant gliomas in adults

26 July 2017

1 reference

Malignant astrocytic glioma: genetics, biology, and paths to treatment

21 January 2018

1 reference

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

Glioma invasion in the central nervous system

21 January 2018

1 reference

Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis.

21 January 2018

1 reference

Angiogenesis in gliomas: biology and molecular pathophysiology

21 January 2018

1 reference

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

Inhibition of angiogenesis and invasion in malignant gliomas

21 January 2018

1 reference

High-grade glioma before and after treatment with radiation and Avastin: initial observations

21 January 2018

1 reference

Molecular mechanisms of glioma invasiveness: the role of proteases

21 January 2018

1 reference

Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion

21 January 2018

1 reference

Molecular approaches to brain tumour invasion

21 January 2018

1 reference

Molecular targets of glioma invasion.

21 January 2018

1 reference

Molecular pathways triggering glioma cell invasion

21 January 2018

1 reference

Dynamic analysis of glioma cells: looking into "movement phenotypes".

21 January 2018

1 reference

Diffuse glioma growth: a guerilla war

21 January 2018

1 reference

Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

21 January 2018

1 reference

Brain tumor stem cells: identification and concepts

21 January 2018

1 reference

Glioma stem cells: a midterm exam.

21 January 2018

1 reference

Cancer: stem cells and brain tumours.

21 January 2018

1 reference

Neural stem cells and the origin of gliomas

21 January 2018

1 reference

Identification of human brain tumour initiating cells

21 January 2018

1 reference

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

Stem cell marker CD133 affects clinical outcome in glioma patients.

21 January 2018

1 reference

Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.

21 January 2018

1 reference

CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells

21 January 2018

1 reference

Neural stem cells, inflammation and NF-kappaB: basic principle of maintenance and repair or origin of brain tumours?

21 January 2018

1 reference

Potential role of NF-kappaB in adult neural stem cells: the underrated steersman?

21 January 2018

1 reference

Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration.

21 January 2018

1 reference

Correlation of N-cadherin expression in high grade gliomas with tissue invasion

21 January 2018

1 reference

Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors

21 January 2018

1 reference

The extracellular space and matrix of gliomas

21 January 2018

1 reference

Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells

21 January 2018

1 reference

Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12.

21 January 2018

1 reference

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

Tenascin-C induced signaling in cancer

21 January 2018

1 reference

Integrins: molecular targets in cancer therapy

21 January 2018

1 reference

Cell migration: integrating signals from front to back

21 January 2018

1 reference

The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades.

21 January 2018

1 reference

ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor

21 January 2018

1 reference

Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis.

21 January 2018

1 reference

Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth

21 January 2018

1 reference

Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration.

21 January 2018

1 reference

HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion

21 January 2018

1 reference

Invadopodia: at the cutting edge of tumour invasion.

21 January 2018

1 reference

Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion

21 January 2018

1 reference

Transforming growth factor-beta (TGF-beta) and brain tumours.

21 January 2018

1 reference

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail

21 January 2018

1 reference

Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration

21 January 2018

1 reference

IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion

21 January 2018

1 reference

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

21 January 2018

1 reference

Ephrin-B3 ligand promotes glioma invasion through activation of Rac1.

21 January 2018

1 reference

EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion

21 January 2018

1 reference

Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients

21 January 2018

1 reference

TWEAK and the central nervous system

21 January 2018

1 reference

The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression

21 January 2018

1 reference

The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors

21 January 2018

1 reference

CXCR4 expression mediates glioma cell invasiveness

21 January 2018

1 reference

LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways

21 January 2018

1 reference

Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma

21 January 2018

1 reference

Targeting the epidermal growth factor receptor in high-grade astrocytomas

21 January 2018

1 reference

Cell surface receptors in lysophospholipid signaling

21 January 2018

1 reference

Focal adhesion kinase: in command and control of cell motility

21 January 2018

1 reference

The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.

21 January 2018

1 reference

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

21 January 2018

1 reference

FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly

21 January 2018

1 reference

Reduced glioma infiltration in Src-deficient mice

21 January 2018

1 reference

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN

21 January 2018

1 reference

Advances in the biology of astrocytomas

21 January 2018

1 reference

PTEN signaling in brain: neuropathology and tumorigenesis.

21 January 2018

1 reference

Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis

21 January 2018

1 reference

FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells

21 January 2018

1 reference

Nuclear factor-kappaB: the enemy within

21 January 2018

1 reference

Nuclear factor-kappaB in development, prevention, and therapy of cancer

21 January 2018

1 reference

Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma

21 January 2018

1 reference

Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion

21 January 2018

1 reference

NF-kappaB controls growth of glioblastomas/astrocytomas

21 January 2018

1 reference

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

Nuclear factor-kappa B: from clone to clinic

21 January 2018

1 reference

NF-kappaB as a potential molecular target for cancer therapy

21 January 2018

1 reference

Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas

21 January 2018

1 reference

Role of synaptojanin 2 in glioma cell migration and invasion

21 January 2018

1 reference

The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma.

21 January 2018

1 reference

The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

21 January 2018

1 reference

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

21 January 2018

1 reference

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.

21 January 2018

1 reference

MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators

21 January 2018

1 reference

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

21 January 2018

1 reference

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

21 January 2018

1 reference

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

21 January 2018

1 reference

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

NF-kappaB in cancer--a friend turned foe.

21 January 2018

1 reference

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

21 January 2018

1 reference

NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition.

21 January 2018

1 reference

A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].

21 January 2018

1 reference

Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide

21 January 2018

1 reference

Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways

21 January 2018

1 reference

Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram

21 January 2018

1 reference

Signaling pathways involved in antioxidant control of glioma cell proliferation.

21 January 2018

1 reference

Cell death in NF-kappaB-dependent tumour cell lines as a result of NF-kappaB trapping by linker-modified hairpin decoy oligonucleotide.

21 January 2018

1 reference

Can NF-kappaB be a target for novel and efficient anti-cancer agents?

21 January 2018

1 reference

Bortezomib as an antitumor agent.

21 January 2018

1 reference

In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas

21 January 2018

1 reference

Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase

21 January 2018

1 reference

Early anti-oxidative and anti-proliferative curcumin effects on neuroglioma cells suggest therapeutic targets

21 January 2018

1 reference

Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors.

21 January 2018

1 reference

Curcumin: from ancient medicine to current clinical trials.

21 January 2018

1 reference

Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides

21 January 2018

1 reference

Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3

21 January 2018

1 reference

Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation

21 January 2018

1 reference

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

21 January 2018

1 reference

A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

21 January 2018

1 reference

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

21 January 2018

1 reference

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

21 January 2018

1 reference

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas

21 January 2018

1 reference

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

21 January 2018

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin

21 January 2018

1 reference

Platelet-derived growth factor (PDGF) and glial tumorigenesis

21 January 2018

1 reference

Deregulated human glioma cell motility: inhibitory effect of somatostatin.

21 January 2018

1 reference

HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells

21 January 2018

1 reference

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

21 January 2018

1 reference

17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion

21 January 2018

1 reference

Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare

21 January 2018

1 reference

The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.09.10

1 reference

26 July 2017

1 reference

PubMed ID

19344303